According to the WHO classification acute myeloid leukemia (AML) is categorized according to cytogenetic and molecular changes \[[@CIT0001]\]. The subgroups with adverse, intermediate and favorable genetics were redefined and incorporated into the major factors predicting treatment-related mortality. Postremission therapy strategies are basically related to cytogenetic abnormalities; therefore for patients with favorable-risk AML repetitive cycles of high-dose cytarabine are considered superior to autologous or allogenic hematopoietic stem cell transplantation (auto- or allo-HSCT) \[[@CIT0002], [@CIT0003]\].

The AML rarely may present in extramedullary form as a primary disease called myeloid sarcoma or as extramedullary relapse (EMR). In recent studies, EMR incidence following allo-HSCT is estimated to be from 5% to 11% and occurs in "sanctuary" sites, e.g. central nervous system, ovary and testis, as well as other anatomical locations including skin, muscle, body cavities, mammary glands, gastrointestinal tract and urinary tract \[[@CIT0004]--[@CIT0007]\]. Up to 2010 as many as 163 cases of AML breast relapse were described but only 36% had karyotype evaluation \[[@CIT0008]\]. We present two patients with AML favorable cytogenetics -- inv(16)(p13;q22); *CBFB* (core binding factor β-chain)*-MYH11* (myosin heavy chain 11 gene) -- and EMR in breast after allo-HSCT.

Case 1. AML M2 according to the French-American-British (FAB) classification with inv(16)(p13;q22) and without *FLT3*(Fms-like tyrosine kinase 3)*-ITD*(internal-tandem duplications) mutation was diagnosed in a 33-year-old female ([Table I](#T0001){ref-type="table"}). She underwent induction chemotherapy according to the DAC-7 protocol (daunorubicin 60 mg/m^2^/day *i.v*., days 1--3; cytarabine 200 mg/m^2^/day, days 1--7; cladribine 5 mg/m^2^/day, days 1--5) and consolidation (HAM: cytarabine 1.5 g/m^2^/day *i.v*., days 1--3; mitoxantrone 10 mg/m^2^, days 3--5 and HD-Ara-C regime: cytarabine 2 g/m^2^ *i.v*., days 1, 3, 5). Complete haematological, cytogenetic and molecular remission (CR) was achieved. Subsequently, 4 cycles of maintenance chemotherapy were administered and the patient was qualified for allo-HSCT from an HLA-matched sibling because of molecular relapse. The myeloablative conditioning regimen included busulfan *i.v*. (3.2 mg/kg/day, days --8 to --5) and cyclophosphamide (60 mg/kg/day, days --4 to --2). Graft-versus-host disease (GvHD) prophylaxis with cyclosporine A (3 mg/kg/day i.v. from --1 day) and methotrexate (15 mg/m^2^, day +1 and 10 mg/m^2^, days +3, +6, +11) was provided. After transfusion of peripheral blood stem cells (PBSC) consisting of 9.5 × 10^6^ CD34+ cells/kg, bone marrow regeneration was achieved (WBC \> 1.0 × 10^9^/l on day +13, ANC \> 0.5 × 10^9^/l on day +17, PLT \> 20 × 10^9^/l on day +9, PLT \> 50 × 10^9^/l on day +11). The post-allo-HSCT period elapsed without signs of GvHD. She was in hematological, cytogenetic and molecular CR with 100% donor chimerism tested with STR-PCR (short tandem repeats-polymerase chain reaction). Breast relapse of AML was diagnosed 25 and 11 months after initial diagnosis and allo-HSCT, respectively. Computed tomography (CT) revealed a polycystic, solid tumor mass of the right breast 70 mm × 65 mm × 32 mm in size ([Figure 1A](#F0001){ref-type="fig"}). The histopathological examination of tumor biopsy ([Figures 1B](#F0001){ref-type="fig"} and [1C](#F0001){ref-type="fig"}) and cytogenetic evaluation ([Figures 1D](#F0001){ref-type="fig"} and [1E](#F0001){ref-type="fig"}) confirmed the AML EMR. Concurrently, molecular relapse was detected as the leukemia-specific *CBFB-MYH11* transcript was identified but still 100% donor chimerism was maintained. Chemotherapy with Ida-FLAG protocol (idarubicin 12 mg/m^2^, days 2--4; fludarabine 30 mg/m^2^, days 1--4; cytarabine 2000 mg/m^2^, days 1--4 and G-CSF up to ANC \> 1 × 10^9^/l, 400 µg/m^2^, day 0) was administered. The molecular CR was obtained and partial regression of breast tumor was observed in CT. Consolidation with the HAM regimen and radiotherapy to the chest field with total 4000 cGy (20 fractions) were performed. The bone marrow and breast CR was maintained in 15 and 11 months follow-up. The retrospective analyses (direct sequencing) of the *c-KIT* gene mutation, exons 8 and 17, were negative in bone marrow aspirated at the time of diagnosis and breast EMR infiltration.

![Breast extramedullary relapse imaging (Case 1): computed tomography (**A**), microscopic (**B** -- proliferation of blast cell with scant cytoplasm and round-oval nuclei with dispersed chromatin and small nucleoli; epithelial structures such as ducts and lobules were preserved with surrounding neoplastic cells (H + E stain, 200×); **C** -- blastic cells strongly express myeloperoxidase (EnVision stain, 200×)) and cytogenetic characteristics (**D** -- result of interphase FISH analysis with CBFB DC Break Apart Probe and CEPX(DXZ1)/Y(DYZ1) (Vysis) show female cell (2 centromere X signals) with separate signals of CBFB gene split apart due to the inversion; **E** -- fusion transcript CBFB-MYH11 type A detected by RT-PCR in examined material (line 1), positive control with RNA isolated from BM cells of another AML M4 patient (line 2), 123 bp marker (line 3))](AMS-10-23028-g001){#F0001}

###### 

Characteristics of patients at initial diagnosis and features of breast extramedullary relapses

  Parameter                                                   Case 1                                    Case 2
  ----------------------------------------------------------- ----------------------------------------- ------------------------------------
  **Characteristics of patients at diagnosis**                                                          
  Age \[years\]                                               33                                        32
  ECOG                                                        1                                         1
  WBC \[× 10^9^/l\]                                           100.903                                   9.53
  PLT \[×10^9^/l\]                                            25.2                                      37
  HGB \[g%\]                                                  9.5                                       8.5
  Extramedullary involvement at diagnosis                     No                                        No
  Blasts in peripheral blood (%)                              78                                        63
  Blasts in bone marrow flow cytometry (%)                    65                                        51
  Immunophenotype in flow cytometry (%):                                                                
   CD13                                                       97.1                                      NS
   CD15                                                       *NS[\*](#TF0001){ref-type="table-fn"}*    *NS*
   CD33                                                       40.4                                      64
   CD34                                                       99.0                                      80
   CD45                                                       NS                                        100
   CD117                                                      95.5                                      95
   HLA-DR                                                     86.4                                      NS
   MPO                                                        92.2                                      NS
  Disease (FAB)                                               AML M2                                    AML M4Eo
  Cytogenetics                                                inv(16) (p13;q22); *CBFB-MYH11*           inv(16) (p13;q22); *CBFB-MYH11*
  Molecular evaluation:                                                                                 
  * FLT3-ITD*                                                 Negative                                  Negative
  * c-KIT*, exons 8 and 17                                    Negative                                  Negative
  **Characteristics of breast extramedullary relapse (ER)**                                             
  Time to ER \[months\]                                       25                                        48
  Localization                                                Unilateral (right breast)                 Bilateral
  Previous acute or chronic GvHD                              No                                        Yes (skin, gastrointestinal tract)
  Bone marrow relapse (BMR)                                   Yes[\*\*](#TF0002){ref-type="table-fn"}   Yes
  Time to BMR \[months\]                                      25                                        19

Not significant

Molecular relapse

Case 2. AML M4EO, *FLT3*-ITD negative, was diagnosed in a 32-year-old female ([Table I](#T0001){ref-type="table"}). The induction treatment started with DAF (daunorubicin 60 mg/m^2^, days 1--3; cytarabine 200 mg/m^2^, days 1--7 and fludarabine 25 mg/m^2^, days 1--5). Consolidation according to the HAM and HD-AraC regimens was performed with haematological, cytogenetic and molecular CR achievement. Subsequently, 8 cycles of maintenance chemotherapy were administered. As the first relapse occurred, the patient was given DAF reinduction followed with HAM consolidation, which initiated the next CR. Allo-HSCT from an HLA-identical unrelated donor was performed with myeloablative conditioning: treosulfan (14 mg/m^2^/day, days 6 to --4), fludarabine (35 mg/m^2^/day, days --6 to --2) and anti-thymocyte globulin (ATG) at a total dose of 15 mg/kg, days --3 to --1. Then she received 10 × 10^6^ CD34+ PBSC/kg. For GvHD prophylaxis the same treatment was provided as in Case 1. Complete hematological reconstitution was accomplished (WBC \> 1.0 × 10^9^/l on day +12, ANC \> 0.5 × 10^9^/l on day +11, PLT \> 20 × 10^9^/l on day +11, PLT \> 50 × 10^9^/l on day +17). Acute GvHD (skin -- grade III, gastrointestinal tract -- grade II according to the Glucksberg clinical classification \[[@CIT0009]\]) was diagnosed on day +9. Additional immunosuppressive treatment with steroid (methylprednisolone) was applied at a dose of 2.5 mg/kg a day and was slowly tapered with complete withdrawal on day +42 following allo-HSCT. Nevertheless, isolated mucosal chronic GvHD persisted. The patient remained in hematological, cytogenetic and molecular CR with 100% donor chimerism tested with the STR-PCR method after allo-HSCT. The EMR concerning entirely both breasts and bone marrow was reported at 48 and 10 months after the initial diagnosis and allo-HSCT respectively. Computed tomography revealed solid tumor masses in both breasts of various sizes. The patient received CLAG-M reinduction (cladribine 5 mg/m^2^, days 1--5; cytarabine 2 g/m^2^, days 1--5; G-CSF 300 mg s.c., days 0--5; mitoxantrone 10 mg/m^2^, days 1--3), breast radiotherapy with a total dose of 1000 Gy and Ida/Ara-C (idarubicin 10 mg/m^2^, days 1--3 and cytarabine 1 g/m^2^, days 1--5) and she achieved CR. The second allo-HSCT from the same unrelated donor (9.52 × 10^6^ CD34+ PBSC/kg) with nonmyeloablative conditioning total body irradiation (TBI) (2 Gy on day --3, fludarabine 35 mg/m^2^ a day, days --4 to --2) and ATG (at total dose 25 mg/kg, days --3 to --1) was performed 20 months following the first allo-HSCT. Bone marrow regeneration was achieved (WBC \> 1.0 × 10^9^/l on day +19, ANC \> 0.5 × 10^9^/l on day +18, PLT \> 20 × 10^9^/l on day +42, PLT \> 50 × 10^9^/l on day +55). The immunosuppressive therapy was stopped on day +34 following the second allo-HSCT without signs of GvHD. The last relapse was observed at 51 months after the initial diagnosis and 5 months following the second allo-HSCT. This patient died one month later due to septic shock. The results of retrospective direct sequencing of exons 8 and 17 of *c-KIT* gene mutations in bone marrow sampled at the time of diagnosis and breast relapse tissue were both negative.

In studies to date on EMR after allo-HSCT, several risk factors have been taken into consideration, but their comprehensive significance remains unclear. Several factors are thought to be associated with higher incidence of EMR including younger age of patients, extramedullary involvement prior to allo-HSCT, advanced AML, and unfavorable karyotype \[[@CIT0010]--[@CIT0013]\]. Moreover, previous GvHD seems to occur more frequently in EMR compared with bone marrow relapse \[[@CIT0006], [@CIT0014]\]. The latest meta-analysis of AML extramedullary relapses in the breast, reported by Cunningham \[[@CIT0008]\], included 163 cases published between 1969 and 2010. All FAB subtypes were nearly equally observed, but karyotypes were available only in 55 cases (36%). In 10 cases (18.2%) inv(16) was described and the remaining AML karyotypes were: 16 (29.1%) -- normal, 9 (16.4%) -- t(8;21), 3 (5.5%) -- t(15;17), 6 (10.9%) -- +8, 11 -- other complex genetic abnormalities. The immunohistochemical markers on leukemic breast tumors which were expressed in all analyzed cases concerned CD33, CD43, CD45 and HLA-DR, without quantifying the percentage of labeled cells.

In the current literature review no molecular markers characteristic for extramedullary relapses were specified. Such investigations were not performed in a group of good prognosis CBF AML patients with extramedullary breast relapses. Although CBF AML compared with other types of AML showed favorable prognosis, almost 50% had early relapse presentation and significant differences in overall survival \[[@CIT0015], [@CIT0016]\]. The presence of *FLT3*-ITD or *c-KIT* mutations was found to be associated with poor prognosis compared to wild-type patients \[[@CIT0017]\]. Both of our patients were negative for *FLT3*-ITD and frequent *c-KIT* mutations but the prognosis after breast EMR differed: the first maintained bone marrow and breast CR (15 and 11 months) after consolidation and radiotherapy; the second one died 6 months after chemotherapy, radiotherapy and second allo-HSCT.

In conclusion, we present 2 patients with CBF AML and development of extramedullary breast relapse after allo-HSCT. Despite similar presentation and molecular marker expression, discrepancies in follow-up were observed. The absence of *FLT3*-ITD transcript and frequent *c-KIT* mutations may exclude the use of these adverse molecular markers in extramedullary breast relapses, but to confirm this correlation molecular research on a larger group of CBF AML patients with isolated extramedullary breast relapses is required.
